Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 4/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16892781 | 0.93 | SMN1; SMN2 (0.39) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL23214397 | 0.93 | SMN1; SMN2 (0.39) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL18030932 | 0.84 | TSHR (0.39) | SMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL27401146 | 0.83 | SMN1; SMN2 (0.35) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL16626943 | 0.80 | PSMB9 (0.33) | — | |
| SCHEMBL20268790 | 0.79 | MME (0.46) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL20268787 | 0.79 | MME (0.46) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL20268789 | 0.79 | MME (0.46) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL21614000 | 0.79 | ALDH1A1 (0.35) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL20529536 | 0.78 | ALDH1A1 (0.35) | MMEACECPA1ACE2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227327-B2 | Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety | Universitetet | Oslo (NO) | 2019-03-12 | — | — | US | disclosed |
| EP-3052135-B1 | INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY | UNIV OSLO (NO) | 2018-07-18 | — | — | EP | disclosed |
| US-20160244431-A1 | Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety | UNIVERSITETET I OSLO (NO) | 2016-08-25 | — | — | US | disclosed |
| EP-3052135-A1 | INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY | Universitetet I Oslo (NO) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049546-A1 | INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY | UNIVERSITETET I OSLO (NO) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244431-A1 | Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety | SLC30A6, DDO, SLC30A7 | MME 459/4885ACE 166/4885CPA1 579/4885 |
| US-10227327-B2 | Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety | SLC30A6, DDO, SLC30A7 | MME 459/4885ACE 166/4885CPA1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.